Technical Forum: Small-Molecule Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Technical Forum: Small-Molecule Synthesis
Pharmaceutical Technology gains insight into approaches for producing aromatic amines.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 48-50

Process chemists face the ongoing challenge of developing efficient routes for synthesizing active pharmeutical ingredients (APIs) and intermediates. Sharing approaches is helpful to resolve those challenges for specific compound classes or compounds. Pharmaceutical Technology gains a perspective from Jacobo Cruces, PhD, and chief scientifc officer of the custom-synthesis provider GalChimia (A Coruña, Spain), for approaches in synthesizing aromatic amines.

Aromatic amines

Jacobo Cruces, PhD and chief scientifc officer of the custom-synthesis provider GalChimia (A Coruña, Spain).


STOCKBYTE, GETTY IMAGES
Aromatic amines are biologically active compounds found throughout the pharmaceutical and agrochemical industries. The development of new methods for their synthesis is still an active area of research. Especially interesting is the transformation of widely available primary anilines and heteroanilines into the corresponding secondary ones (1).

Direct alkylation is typically accomplished by reaction with an alkyl halide or similar reagent in the presence of a base, but it is a deceptively simple transformation because in many cases efficient N-monoalkylation of primary anilines is not possible because of over-alkylation, which affords tertiary anilines or quaternary ammonium salts as byproducts. Other protocols for monoalkylation use a temporary protecting group (e.g., carbamate, benzyl) that allows the introduction of a single alkyl group followed by removal of the protecting group (thereby introducing two additional steps in the process). However, due to their toxic nature, the use of many of the alkylating agents must be avoided, particularly in the last step of the synthesis of APIs and active compounds. Two widely used methods of N-alkylation are reductive amination with carbonyl derivatives and amide reduction. These methods are selective, but the reaction conditions are somewhat harsh, as strong reducing reagents (i.e., metal hydrides and hydrogen) must be used, and chemoselectivity can be troublesome. Additional problems are involved during the scale-up because reducing agents are hazardous.


Figure 1: Copper-promoted alkylation of aromatic amines with alkylboronic acids. (FIGURE 1 IS COURTESY OF GALCHIMIA)
The formation of C–N bonds via cross-coupling reactions is an essential methodology for preparing nitrogen-containing compounds. Recently, different transition metal-promoted reactions have been developed for the synthesis of secondary amines: catalytic systems for N-alkylation of amines with alcohols using ruthenium, rhodium, or iridium catalysts based on the "borrowing hydrogen" approach (2–15). Most of these reactions must be run at high temperature (i.e., up to 180 °C) or can be applied to a restricted range of amines and alcohols. Other approaches rely on the hydroamination of alkenes or alkynes, but again in some cases, the selectivity is low or the substrate scope is not very extensive (16–21).

Copper-promoted carbon–nitrogen bond-forming cross-coupling reactions of NH-containing substrates with arylboronic acids have emerged as a powerful synthetic method since the initial reports by Chan, Lam and Evans (22–25). In recent years, the catalytic version of the reaction (26–28) and the arylation of amines under base and ligand-free conditions (29–31) have been reported. Although the Chan-Lam reaction has been applied to different boronic acids, alkylboronic acids rarely act as effective reagents for this reaction presumably because of their low reactivity toward transmetallation with copper salts. Until 2008, only two papers reported the use of an alkylboronic acid (cyclopropyl- and cyclohexylboronic acid) in this kind of coupling reactions with NH-containing substrates (restricted to substrates with increased NH acidity such as amides and indoles) (32–34).


CSR and sustainability forum
GalChimia has developed a procedure for the selective N-monomethylation of aromatic amines by means of a cross-coupling reaction between anilines and methylboronic acid (35). The reaction is carried out in refluxing dioxane, and it allows a number of structurally and electronically diverse anilines to be monomethylated in a single step. The use of a copper promotor has two main advantages compared with other metal catalysts such as palladium. First, it is much cheaper than precious metals. Second, it is not a heavy metal, and it is therefore less toxic, something especially critical in the last steps of API production.

Recently GalChimia expanded the previous Chan-Lam protocol to carry out the N-monoalkylation of other (hetero)aromatic amines using a wide pool of alkylboronic acids, including propyl-, iso-propyl-, butyl-, iso-butyl-, pentyl-, iso-pentyl-, cyclohexyl-, cyclohexylethyl- and phenylethylboronic acid (36). The use of phenylethylboronic acid opens a very attractive venue for the preparation of phenylethylamines, a widespread common motif among pharmacologically interesting compounds.


Patricia Van Arnum
Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here